Current NDC auxiliary source row compounder:2039

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 79559-4079
Product Ndc: 79559-4079
Product Ndc Digits: 795594079
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: S-TA079
Proprietary Name Suffix: [empty]
Nonproprietary Name: S-TA079
Dosage Form Name: PELLET, IMPLANTABLE
Route Name: SUBCUTANEOUS
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: F. H. Investments. Inc. DBA Asteria Health
Establishment Name: F. H. Investments. Inc. DBA Asteria Health
Establishment Fei: [empty]
Substance Name: TESTOSTERONE; ANASTROZOLE
Active Ingredients Info: 75 mg/79 mg; 4 mg/79 mg
History Active Ingredients Raw: TESTOSTERONE; ANASTROZOLE
History Active Ingredients Info Raw: 75 mg/79 mg; 4 mg/79 mg
History Dosage Raw: PELLET, IMPLANTABLE
Dea Schedule: CIII
Package Ndc Raw: 79559-4079-1
Package Ndc: 79559-4079-1
Package Ndc Digits: 7955940791
Package Ndc11: 79559407901
Package Description: 79 mg in 1 VIAL, PLASTIC (79559-4079-1)
Reporting Period Raw: 2025-2
Reporting Period: 2025-2
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:2039
Source Row Number: 2039
Source Row Hash: 5faeeba7d43c705aebf1dca55691591fee0f5f12fec3cd869941e0b8c30a5d62
Import Run Id: 20261024T140201Z
Loaded At: 2026-10-24 14:07:01

Exact raw FDA source fields#

{
    "ROUTENAME": "SUBCUTANEOUS",
    "PRODUCTNDC": "79559-4079",
    "DEASCHEDULE": "CIII",
    "LABELERNAME": "F. H. Investments. Inc. DBA Asteria Health",
    "SUBSTANCENAME": "TESTOSTERONE; ANASTROZOLE",
    "DOSAGEFORMNAME": "PELLET, IMPLANTABLE",
    "NDCPACKAGECODE": "79559-4079-1",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "S-TA079",
    "REPORTINGPERIOD": "2025-2",
    "NONPROPRIETARYNAME": "S-TA079",
    "PACKAGEDESCRIPTION": "79 mg in 1 VIAL, PLASTIC (79559-4079-1) ",
    "ACTIVEINGREDIENTSINFO": "75 mg/79 mg; 4 mg/79 mg",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:2039
Source Row Number: 2039
Status Scope: package
Lookup Ndc: 79559-4079-1
Lookup Ndc Digits: 7955940791
Product Ndc: 79559-4079
Product Ndc Digits: 795594079
Package Ndc: 79559-4079-1
Package Ndc Digits: 7955940791
Package Ndc11: 79559407901
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2025-2
Reporting Period: 2025-2
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: 5faeeba7d43c705aebf1dca55691591fee0f5f12fec3cd869941e0b8c30a5d62
Import Run Id: 20261024T140201Z
Loaded At: 2026-10-24 14:07:01